Back HIV Treatment

HIV Treatment

HIV Drug Therapy: Lower-dose Efavirenz Equally Effective with Fewer Side Effects

A reduced dose of efavirenz (Sustiva or Stocrin) for first-line HIV therapy suppressed viral load as well as the standard dose, but was associated with fewer characteristic side effects, researchers reported at the recent HIV Drug Therapy 2014 meeting in Glasgow. A related study found that half the dose maintained viral suppression in people with high efavirenz levels in their blood.

alt

Read more:

Happy Holidays from HIVandHepatitis.com

alt

HIV in the UK: 76% Diagnosed, 90% on Treatment, 90% Undetectable

The United Kingdom's annual epidemiological report, released in late November, shows that the country already provides HIV treatment to 90% of people accessing clinical services and that 90% of those on treatment have an undetectable viral load. But the country has a long way to go in ensuring that people with HIV are aware of their HIV status -- only 76% of people living with HIV have been diagnosed. The problem is particularly acute in black African communities, as only 62% of African heterosexual men and 69% of African heterosexual women living with HIV have been diagnosed.

alt

Read more:

HIV Drug Therapy: Efavirenz Not Linked to Higher Suicide Risk in D:A:D Cohort

People taking antiretroviral therapy (ART) regimens containing the NNRTI efavirenz (Sustiva) were not more likely to die due to suicide or psychiatric illness than those taking other drugs in the large D:A:D cohort, researchers reported last month at the HIV Drug Therapy 2014 meeting in Glasgow.

alt

Read more:

European Commission Approves Boosted Darunavir Combo Rezolsta for HIV

The European Commission last month approved a new fixed-dose coformulation -- dubbed Rezolsta -- containing the HIV protease inhibitor darunavir boosted with the novel pharmacoenhancer cobicistat, Janssen recently announced. The combination is currently being evaluated for U.S. approval.

alt

Read more: